FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products - FDA Oncology

FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products – FDA Oncology

FDA Oncology shared on X/Twitter:

“FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products.”

Further details.
Source: FDA Oncology/X

cancer dihydropyrimidine dehydrogenase DPD FDA Oncology fluorouracil OncoDaily Oncology safety labeling changes